Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Knowledge of Treatment Assignment Affect Patient Report Of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials

(2021) Jessica K. Roydhouse et al.   VALUE IN HEALTH

Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities

(2021) Laura M. Spring et al.   ONCOLOGIST

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer

(2020) S. Adams et al.   ANNALS OF ONCOLOGY

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer

(2020) Yvonne Brandberg et al.   BREAST CANCER RESEARCH AND TREATMENT

How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods

(2020) Yosra Mouelhi et al.   Health and Quality of Life Outcomes

Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015)

(2018) Fatima Cardoso et al.   BREAST

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States

(2018) S. Nolte et al.   EUROPEAN JOURNAL OF CANCER

Long-Term and Latent Side Effects of Specific Cancer Types

(2017) Nana Gegechkori et al.   MEDICAL CLINICS OF NORTH AMERICA

Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust

(2016) Johannes M. Giesinger et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies

(2016) Matthew J. Page et al.   PLoS One

Quality of life and metastatic breast cancer: the role of body image, disease site, and time since diagnosis

(2015) Sara I. McClelland et al.   QUALITY OF LIFE RESEARCH

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2012) K. Cocks et al.   EUROPEAN JOURNAL OF CANCER

Determining the non-inferiority margin for patient reported outcomes

(2011) Christoph Gerlinger et al.   PHARMACEUTICAL STATISTICS

Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2010) Kim Cocks et al.   JOURNAL OF CLINICAL ONCOLOGY